Beta Bionics Inc. (BBNX) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 12.82 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 55.4% Gross Margin
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While BBNX currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($19.11) and Max Pain ($18.46) forces dealer call-delta covering toward $34.35.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Beta Bionics Inc. (BBNX) slipped -1.51% to $17.58, trading at 37% of its 52-week range ($8.8 – $32.71). Stretched risk/reward at current multiples (-22% return on capital) under elevated 10-year interest-rate pressure.
Gainers Pulmonx (NASDAQ:LUNG) stock increased by 33.1% to $2.63 during Wednesday's regular session. The company's market cap stands at $85.0 million. As per the press release, Q3 earnings came out yesterday.
TD Cowen analyst Mathew Blackman maintains Beta Bionics (NASDAQ:BBNX) with a Hold and raises the price target from $18 to $21.
Moby summary of Beta Bionics, Inc.'s Q3 2026 earnings call
Piper Sandler analyst Matt O'Brien reiterates Beta Bionics (NASDAQ:BBNX) with a Overweight and raises the price target from $20 to $24.
2026-10-28. The following slide deck was published by Beta Bionics, Inc.
Revenue hit $35.5 million with 30% growth as Mint patch pump nears Q1 2027 launch.
Beta Bionics (NASDAQ:BBNX) reported third-quarter net sales of $35.5 million, up about 30% from a year earlier, as new patient starts and recurring revenue from its pharmacy-channel user base supported growth. The compan
After the Oct. 27, 2026 US session, SNTI and NEXR led after-hours gainers, while SCKT and SHFSW led decliners, with deal, earnings, and listing news noted.
Beta Bionics, Inc. (BBNX) Q3 2026 Earnings Call October 27, 2026 4:30 PM EDTCompany ParticipantsBlake Beber - Head of Investor RelationsSean Saint -...
Beta Bionics Q3 revenue matched estimates, but shares fell as full-year guidance missed consensus and Mint/3D launch timing raised concerns.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +53.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on BBNX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for BBNX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Beta Bionics Inc. (BBNX) ranks #776 by composite RQD confidence (36/100, grade D-) and #364 by equity capitalization ($955.8M). Within this direct 5-issuer industry benchmark cohort, IRMD leads on earnings valuation at 48.8x trailing P/E, while IRMD leads on capital efficiency and profitability with 37.7% ROIC and 76.7% gross margin. IRMD currently holds the highest overall quantitative score in the immediate peer group at 68/100 (C+) compared with BBNX at 36/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BBNX
ACTIVE
Beta Bionics Inc. | D- | 36/100 | — | 55.4% | -22.1% | -1.51% | $955.8M | Benchmark Subject |
| IART Integra LifeSciences Holdings Corporation | E | 32/100 | — | 50.9% | -35.0% | +4.82% | $998.2M | /iart-vs-bbnx → |
| SIBN SI-BONE Inc. | D | 48/100 | — | 79.6% | -10.3% | +2.66% | $1.00B | /sibn-vs-bbnx → |
| SGP SpyGlass Pharma Inc. | D- | 41/100 | — | — | -35.0% | -1.06% | $1.09B | /sgp-vs-bbnx → |
| IRMD iRadimed Corporation | C+ | 68/100 | 48.8x | 76.7% | 37.7% | +2.16% | $1.10B | /irmd-vs-bbnx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Beta Bionics Inc. (BBNX) reported GAAP revenue of $100.3M (+53.9% vs. FY2024 revenue of $65.1M , and +735.8% cumulative change since FY2023) , GAAP net income of -$73.2M, operating cash flow of -$50.9M, and free cash flow of -$56.2M (-8.8% YoY). On the balance sheet, BBNX closed FY2025 with $328.7M in total assets against $0 in total debt (Altman Z-Score: 12.82, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $100.3M | -$73.2M | -$50.9M | -$56.2M | $328.7M | — |
| FY2024 (FY) | 2024-12-31 | $65.1M | -$54.8M | -$48.3M | -$51.7M | $149.6M | — |
| FY2023 (FY) | 2023-12-31 | $12.0M | -$44.1M | -$32.4M | -$32.4M | — | — |
As of 2026-11-01, Beta Bionics Inc. (NASDAQ: BBNX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $17.58 (-1.51% 1D, market cap $955.8M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, BBNX ranks #776 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), BBNX carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 55.4%, and ROIC of -22.1%. By comparison, IART (Integra LifeSciences Holdings Corporation) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $998.2M) and SIBN (SI-BONE Inc.) posts a D grade (48/100 RQD, P/E N/A, ROIC -10.3%, cap $1.00B). Among the 5-stock peer group, IRMD leads on earnings multiple (48.8x) while IRMD leads on capital efficiency (37.7% ROIC).
Per BBNX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001674632), Beta Bionics Inc. generated $100.3M in revenue (+53.9% YoY), -$73.2M in net income, and -$56.2M in free cash flow against $328.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
BBNX last traded at $17.58 (-1.51% on volume of 1,288,511 shares), positioning the stock -8.01% below its 50-day simple moving average ($19.11) and +18.62% above its 200-day simple moving average ($14.82). Across its 52-week range of $8.80 to $32.71, BBNX sits at the 36.7% percentile with a 14-day RSI of 41.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($15.38 to $19.78).
Why BBNX Stock slipped -1.51% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-22% return on capital) under elevated 10-year interest-rate pressure.